Vaccine Platform for Prevention of Tuberculosis and Mother-to-Child Transmission of HIV-1 through Breastfeeding

word count: 186 Text word count: 4,624 AC CE PT ED Copyright © 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. J. Virol. doi:10.1128/JVI.00707-07 JVI Accepts, published online ahead of print on 27 June 2007 on O cber 2, 2017 by gest http/jvi.asm .rg/ D ow nladed fom

[1]  A. McMichael,et al.  Combined single‐clade candidate HIV‐1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference , 2007, European journal of immunology.

[2]  S. Rowland-Jones,et al.  Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen , 2006, Retrovirology.

[3]  J. Gatell,et al.  Progress towards an HIV vaccine based on recombinant Bacillus Calmette–Guérin: failures and challenges , 2006, Expert review of vaccines.

[4]  S. Rowland-Jones,et al.  Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag Vaccine , 2006, Journal of Virology.

[5]  C. Dye,et al.  The Development and Impact of Tuberculosis Vaccines , 2006, Cell.

[6]  B. Haynes,et al.  Generation of CD8+ T-Cell Responses by a Recombinant Nonpathogenic Mycobacterium smegmatis Vaccine Vector Expressing Human Immunodeficiency Virus Type 1 Env , 2006, Journal of Virology.

[7]  A. McMichael,et al.  Induction of Human Immunodeficiency Virus Type 1-Specific T Cells by a Bluetongue Virus Tubule-Vectored Vaccine Prime-Recombinant Modified Virus Ankara Boost Regimen , 2005, Journal of Virology.

[8]  M. Kanekiyo,et al.  Priming-Boosting Vaccination with Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and a Nonreplicating Vaccinia Virus Recombinant Leads to Long-Lasting and Effective Immunity , 2005, Journal of Virology.

[9]  S. Rowland-Jones,et al.  Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants. , 2005, Vaccine.

[10]  S. Rowland-Jones,et al.  Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine , 2005, AIDS.

[11]  M. Goldman,et al.  T cell‐mediated immune responses in human newborns: ready to learn? , 2005, Clinical and experimental immunology.

[12]  A. Williamson,et al.  Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. , 2005, Vaccine.

[13]  Jessica M Malenfant,et al.  CD107a as a functional marker for the identification of natural killer cell activity. , 2004, Journal of immunological methods.

[14]  H. McShane,et al.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans , 2004, Nature Medicine.

[15]  C. Leclerc,et al.  Neonatal adaptive immunity comes of age , 2004, Nature Reviews Immunology.

[16]  Wayne C Koff,et al.  HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.

[17]  Franca Ronchese,et al.  The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. , 2004, Journal of immunological methods.

[18]  S. Rowland-Jones,et al.  Mature CD8(+) T lymphocyte response to viral infection during fetal life. , 2003, The Journal of clinical investigation.

[19]  M. Horwitz,et al.  A New Vaccine against Tuberculosis Affords Greater Survival after Challenge than the Current Vaccine in the Guinea Pig Model of Pulmonary Tuberculosis , 2003, Infection and Immunity.

[20]  C. Rousseau,et al.  Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. , 2003, The Journal of infectious diseases.

[21]  W. Moss,et al.  Immunization of children at risk of infection with human immunodeficiency virus. , 2003, Bulletin of the World Health Organization.

[22]  G. Hussey,et al.  Neonatal mycobacterial specific cytotoxic T‐lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies , 2002, Immunology.

[23]  M. Newport,et al.  Influence of Mycobacterium bovis Bacillus Calmette-Guérin on Antibody and Cytokine Responses to Human Neonatal Vaccination1 , 2002, The Journal of Immunology.

[24]  B. Richardson,et al.  Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: A randomized clinical trial. , 2001, JAMA.

[25]  P. Goulder,et al.  Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. , 2001, British medical bulletin.

[26]  C. Siegrist.  Neonatal and early life vaccinology. , 2001, Vaccine.

[27]  M. Newport,et al.  Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. , 2001, European journal of immunology.

[28]  M. Prevost,et al.  Lipoprotein Access to MHC Class I Presentation During Infection of Murine Macrophages with Live Mycobacteria1 , 2001, The Journal of Immunology.

[29]  M. Newport,et al.  Prevention of Infectious Diseases by Neonatal and Early Infantile Immunization: Prospects for the New Millennium* , 2001, Current opinion in infectious diseases.

[30]  A. McMichael,et al.  Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. , 2000, Nature Medicine.

[31]  M. Newport,et al.  Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. , 1999, Journal of immunology.

[32]  A. R. Sills,et al.  Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. , 1999, Vaccine.

[33]  C. Rouzioux,et al.  Early HIV-specific cytotoxic T lymphocytes and disease progression in children born to HIV-infected mothers. , 1998, AIDS research and human retroviruses.

[34]  Marion Becker,et al.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara , 1998, Nature Medicine.

[35]  J. Haas,et al.  Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage , 1998, Journal of Virology.

[36]  A. McMichael.  HIV vaccines , 1998, Annual review of immunology.

[37]  J. Sullivan,et al.  Early HIV-1 Envelope-specific Cytotoxic T Lymphocyte Responses in Vertically Infected Infants , 1997, The Journal of experimental medicine.

[38]  R. Phillpotts,et al.  A simple device for the exposure of animals to infectious microorganisms by the airborne route , 1997, Epidemiology and Infection.

[39]  P. Sharp,et al.  Codon usage in the Mycobacterium tuberculosis complex. , 1996, Microbiology.

[40]  D E Snider,et al.  Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. , 1995, JAMA.

[41]  J. Sullivan,et al.  HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. , 1995, Journal of immunology.

[42]  C S Berkey,et al.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. , 1994, JAMA.

[43]  M. Hanson,et al.  Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine , 1993, The Journal of experimental medicine.

[44]  N. Letvin,et al.  Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. , 1993, Journal of immunology.

[45]  C. DeLisi,et al.  An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Lagrange,et al.  The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. , 1988, Journal of biological standardization.

[47]  O. Wasz‐Höckert,et al.  BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. , 1984, Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose.